慢性乙型肝炎合并非酒精性脂肪性肝病的研究进展

刘伟鸿; 李磊

doi:10.3969/j.issn.1001-5256.2021.12.035

慢性乙型肝炎合并非酒精性脂肪性肝病的研究进展

DOI: 10.3969/j.issn.1001-5256.2021.12.035

刘伟鸿,
李磊^,

首都医科大学附属北京佑安医院肝病消化中心，北京 100069

基金项目:

北京市卫生系统高层次卫生人才 (2013-3-073);

十三五“艾滋病与病毒性肝炎等重大传染病防治”科技重大专项 (2017ZX10203202003008);

北京市医院管理局消化内科学科协同发展中心 (XXZ0303)

详细信息

通信作者:
李磊，m13699119545@163.com

中图分类号: R512.62; R575.5
计量
- 文章访问数: 398
- HTML全文浏览量: 96
- PDF下载量: 84
- 被引次数: 0
出版历程
- 收稿日期: 2021-04-21
- 录用日期: 2021-05-26
- 出版日期: 2021-12-20

Advances in chronic hepatitis B with nonalcoholic fatty liver disease

Weihong LIU,
Lei LI^,

Center of Hepatic and Digestive Diseases, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, China

Research funding:

High Level Health Talents in Beijing Health System (2013-3-073);

The 13th Five-Year Plan "Prevention and Treatment of Major Infectious Diseases such as AIDS and Viral Hepatitis" Major Science and Technology Project (2017ZX10203202003008);

Collaborative Development Center of Department of Gastroenterology, Beijing Hospital Administration (XXZ0303)

摘要

摘要: 近年来，随着人们生活方式的改变，非酒精性脂肪性肝病(NAFLD)的发病率持续增加，慢性乙型肝炎(CHB)合并NAFLD的患者也日益增多，并逐渐被临床医师所重视。但目前两者之间的相互作用及临床预后等尚不明确。通过对CHB合并NAFLD的相关文献进行归纳总结，综述了CHB合并NAFLD的相互影响、诊治及预后等方面的研究进展，以期为该类疾病的充分认识及积极诊疗提供帮助。
- 乙型肝炎, 慢性 /
- 非酒精性脂肪性肝病 /
- 预后
Abstract: With the change in lifestyle in recent years, the incidence rate of nonalcoholic fatty liver disease (NAFLD) keeps increasing, and there is also a gradual increase in the number of patients with both chronic hepatitis B (CHB) and NAFLD, which has been taken seriously by clinicians. However, the interaction between the two diseases and their clinical prognosis remain unclear. This article reviews the interaction, diagnosis, treatment, and prognosis of CHB with NAFLD by summarizing related articles on CHB with NAFLD, in order to provide help for the comprehensive understanding and active diagnosis and treatment of such diseases.
- Hepatitis B, Chronic /
- Non-alcoholic Fatty Liver Disease /
- Prognosis

HTML全文

参考文献(46)

[1]	YOUNOSSI Z, TACKE F, ARRESE M, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J]. Hepatology, 2019, 69(6): 2672-2682. DOI: 10.1002/hep.30251.
[2]	LAZARUS JV, COLOMBO M, CORTEZ-PINTO H, et al. NAFLD - sounding the alarm on a silent epidemic[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(7): 377-379. DOI: 10.1038/s41575-020-0315-7.
[3]	LONARDO A, BYRNE CD, CALDWELL SH, et al. Global epidemiology of nonalcoholic fatty liver disease: Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64(4): 1388-1389. DOI: 10.1002/hep.28584.
[4]	WANG YH, GAO Y. Research progress in diagnosis and treatment of non-alcoholic fatty liver disease combinated with type 2 diabetes mellitus[J]. J Jilin Univ(Med Edit), 2020, 46(6): 1324-1331. DOI: 10.13481/j.1671-587x.20200634. 王雨涵, 高影. 非酒精性脂肪性肝病并发2型糖尿病诊断和治疗的研究进展[J]. 吉林大学学报(医学版), 2020, 46(6): 1324-1331. DOI: 10.13481/j.1671-587x.20200634.
[5]	PERUMPAIL BJ, KHAN MA, YOO ER, et al. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease[J]. World J Gastroenterol, 2017, 23(47): 8263-8276. DOI: 10.3748/wjg.v23.i47.8263.
[6]	SETO WK, YUEN MF. Nonalcoholic fatty liver disease in Asia: Emerging perspectives[J]. J Gastroenterol, 2017, 52(2): 164-174. DOI: 10.1007/s00535-016-1264-3.
[7]	HANIF H, KHAN MM, ALI MJ, et al. A new endemic of concomitant nonalcoholic fatty liver disease and chronic hepatitis B[J]. Microorganisms, 2020, 8(10): 1526. DOI: 10.3390/microorganisms8101526.
[8]	HUI R, SETO WK, CHEUNG KS, et al. Inverse relationship between hepatic steatosis and hepatitis B viremia: Results of a large case-control study[J]. J Viral Hepat, 2018, 25(1): 97-104. DOI: 10.1111/jvh.12766.
[9]	WANG CC, CHENG PN, KAO JH. Systematic review: Chronic viral hepatitis and metabolic derangement[J]. Aliment Pharmacol Ther, 2020, 51(2): 216-230. DOI: 10.1111/apt.15575.
[10]	SU HJ, KAO JH, TSENG TC, et al. Pathologic findings of patients with nonalcoholic fatty liver disease and the impact of concurrent hepatitis B virus infection in Taiwan[J]. J Formos Med Assoc, 2020, 119(10): 1476-1482. DOI: 10.1016/j.jfma.2020.05.027.
[11]	PAIS R, RUSU E, ZILISTEANU D, et al. Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease[J]. Eur J Intern Med, 2015, 26(1): 30-36. DOI: 10.1016/j.ejim.2014.12.001.
[12]	ZHU L, JIANG J, ZHAI X, et al. Hepatitis B virus infection and risk of non-alcoholic fatty liver disease: A population-based cohort study[J]. Liver Int, 2019, 39(1): 70-80. DOI: 10.1111/liv.13933.
[13]	LU HH, CHEN QQ, SUN FF, et al. Progress on chronic hepatitis B complicated with non-alcoholic fatty liver disease[J/CD]. Chin J Liver Dis(Electronic Edition), 2020, 12(3): 12-16. DOI: 10.3969/j.issn.1674-7380.2020.03.003. 陆慧慧, 陈琦琪, 孙芳芳, 等. 慢性乙型肝炎合并非酒精性脂肪性肝病研究进展[J/CD]. 中国肝脏病杂志(电子版), 2020, 12(3): 12-16. DOI: 10.3969/j.issn.1674-7380.2020.03.003.
[14]	WU YL, PENG XE, ZHU YB, et al. Hepatitis B virus X protein induces hepatic steatosis by enhancing the expression of liver fatty acid binding protein[J]. J Virol, 2016, 90(4): 1729-1740. DOI: 10.1128/JVI.02604-15.
[15]	JOO EJ, CHANG Y, YEOM JS, et al. Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: A cohort study[J]. Hepatology, 2017, 65(3): 828-835. DOI: 10.1002/hep.28917.
[16]	HUANG J, JING M, WANG C, et al. The impact of hepatitis B virus infection status on the prevalence of nonalcoholic fatty liver disease: A population-based study[J]. J Med Virol, 2020, 92(8): 1191-1197. DOI: 10.1002/jmv.25621.
[17]	ZHONG GC, WU YL, HAO FB, et al. Current but not past hepatitis B virus infection is associated with a decreased risk of nonalcoholic fatty liver disease in the Chinese population: A case-control study with propensity score analysis[J]. J Viral Hepat, 2018, 25(7): 842-852. DOI: 10.1111/jvh.12878.
[18]	ZHAO Z, WANG KF, CHEN L, et al. Higher proportion of hepatitis B-related hepatocellular carcinoma combined with metabolic diseases in patients receiving antiviral therapy[J]. Chin J Hepatol, 2021, 29(4): 344-349. DOI: 10.3760/cma.j.cn501113-20201124-00628. 赵洲, 王凯风, 陈丽, 等. 接受过抗病毒治疗的乙型肝炎相关肝细胞癌患者合并代谢性疾病的比例更高[J]. 中华肝脏病杂志, 2021, 29(4): 344-349. DOI: 10.3760/cma.j.cn501113-20201124-00628.
[19]	GAO H, KUANG Z, ZHONG CX, et al. Prevalence and risk factors of nonalcoholic fatty liver disease in patients with chronic hepatitis B receiving antiviral therapy[J]. Chin J Hepatol, 2019, 27(5): 347-351. DOI: 10.3760/cma.j.issn.1007-3418.2019.05.005. 高慧, 匡哲, 钟春秀, 等. 接受抗病毒治疗的慢性乙型肝炎患者非酒精性脂肪性肝病的患病率及其危险因素分析[J]. 中华肝脏病杂志, 2019, 27(5): 347-351. DOI: 10.3760/cma.j.issn.1007-3418.2019.05.005.
[20]	WANG MF, LIN S, WU YL, et al. The correlation between fatty liver disease and serum and histological viral parameters in patients with chronic hepatitis B[J]. Chin J Infect Dis, 2016, 34(3): 141-145. DOI: 10.3760/cma.j.issn.1000-6680.2016.03.002. 王明芳, 林苏, 吴银莲, 等. 慢性乙型肝炎患者肝脂肪变性与血清、肝组织病毒因素的关系[J]. 中华传染病杂志, 2016, 34(3): 141-145. DOI: 10.3760/cma.j.issn.1000-6680.2016.03.002.
[21]	KARACAER Z, OKUR G, CERMIK H, et al. Is there an influence of hepatic steatosis on fibrosis and necroinflammation in young patients with chronic viral hepatitis B?[J]. Postgrad Med, 2016, 128(7): 697-700. DOI: 10.1080/00325481.2016.1221733.
[22]	MAK LY, HUI RW, FUNG J, et al. Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B[J]. J Hepatol, 2020, 73(4): 800-806. DOI: 10.1016/j.jhep.2020.05.040.
[23]	TURER AT, BROWNING JD, AYERS CR, et al. Adiponectin as an independent predictor of the presence and degree of hepatic steatosis in the Dallas Heart Study[J]. J Clin Endocrinol Metab, 2012, 97(6): e982-e986. DOI: 10.1210/jc.2011-3305.
[24]	HSU CS, LIU WL, CHAO YC, et al. Adipocytokines and liver fibrosis stages in patients with chronic hepatitis B virus infection[J]. Hepatol Int, 2015, 9(2): 231-242. DOI: 10.1007/s12072-015-9616-2.
[25]	Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
[26]	BEDOSSA P, PATEL K. Biopsy and noninvasive methods to assess progression of nonalcoholic fatty liver disease[J]. Gastroenterology, 2016, 150(8): 1811-1822. e4. DOI: 10.1053/j.gastro.2016.03.008.
[27]	TINIAKOS DG. Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis: Histological diagnostic criteria and scoring systems[J]. Eur J Gastroenterol Hepatol, 2010, 22(6): 643-650. DOI: 10.1097/MEG.0b013e32832ca0cb.
[28]	National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association, Fatty Liver Expert Committee, Chinese Medical Doctor Associ- ation. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: A 2018 update[J]. J Clin Hepatol, 2018, 34(5): 947-957. DOI: 10.3969/j.issn.1001-5256.2018.05.007. 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34(5): 947-957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.
[29]	KLEINER DE. Histopathology, grading and staging of nonalcoholic fatty liver disease[J]. Minerva Gastroenterol Dietol, 2018, 64(1): 28-38. DOI: 10.23736/S1121-421X.17.02445-X.
[30]	HUANG CM, HU ZW, NIE YQ, et al. The value of non-invasive diagnostic model in predicting liver fibrosis in patients with chronic hepatitis B combined with non-alcoholic fatty liver disease[J]. Chin J Gastroenterol Hepatol, 2019, 28(8): 915-918. DOI: 10.3969/j.issn.1006-5709.2019.08.018. 黄春明, 胡中伟, 聂玉强, 等. 无创诊断模式预测慢性乙型肝炎合并非酒精性脂肪肝患者肝纤维化的价值[J]. 胃肠病学和肝病学杂志, 2019, 28(8): 915-918. DOI: 10.3969/j.issn.1006-5709.2019.08.018.
[31]	MU R, LU LG. Advances in the application of magnetic resonance imaging in hepatic fat quantification in patients with nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2020, 36(6): 1366-1369. DOI: 10.3969/j.issn.1001-5256.2020.06.038. 穆容, 陆伦根. 磁共振成像技术在非酒精性脂肪性肝病肝脂肪定量中的应用[J]. 临床肝胆病杂志, 2020, 36(6): 1366-1369. DOI: 10.3969/j.issn.1001-5256.2020.06.038.
[32]	PYDYN N, MI KUS K, JURA J, et al. New therapeutic strategies in nonalcoholic fatty liver disease: A focus on promising drugs for nonalcoholic steatohepatitis[J]. Pharmacol Rep, 2020, 72(1): 1-12. DOI: 10.1007/s43440-019-00020-1.
[33]	XIAO QQ, WANG MY, FAN JG. Brief introduction of APASL clinical practice guidelines on metabolic associated fatty liver disease (Treatment Part)[J]. J Clin Hepatol, 2021, 37(1): 41-45. DOI: 10.3969/j.issn.1001-5256.2021.01.009. 肖倩倩, 王梦雨, 范建高. 亚太肝病研究学会代谢相关脂肪性肝病临床诊疗指南(治疗部分)简介[J]. 临床肝胆病杂志, 2021, 37(1): 41-45. DOI: 10.3969/j.issn.1001-5256.2021.01.009.
[34]	KIM DS, JEON MY, LEE HW, et al. Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir[J]. Clin Mol Hepatol, 2019, 25(3): 283-293. DOI: 10.3350/cmh.2018.0054.
[35]	JIN X, CHEN YP, YANG YD, et al. Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B[J]. PLoS One, 2012, 7(3): e34198. DOI: 10.1371/journal.pone.0034198.
[36]	LI JQ. The clinical significance of blood lipid, blood glucose and liver function detection in diagnosis and treatment of fatty liver patients[J]. Chin J Clin Pathol, 2017, 9(4): 211-213. DOI: 10.3969/j.issn.1674-7151.2017.04.005. 李加庆. 联合检测血脂血糖和肝功能对脂肪肝患者诊断和治疗的意义[J]. 实用检验医师杂志, 2017, 9(4): 211-213. DOI: 10.3969/j.issn.1674-7151.2017.04.005.
[37]	DOUMAS M, IMPRIALOS K, DIMAKOPOULOU A, et al. The role of statins in the management of nonalcoholic fatty liver disease[J]. Curr Pharm Des, 2018, 24(38): 4587-4592. DOI: 10.2174/1381612825666190117114305.
[38]	ATHYROS VG, BOUTARI C, STAVROPOULOS K, et al. Statins: An under-appreciated asset for the prevention and the treatment of NAFLD or NASH and the related cardiovascular risk[J]. Curr Vasc Pharmacol, 2018, 16(3): 246-253. DOI: 10.2174/1570161115666170621082910.
[39]	ZHAO B, QI YH, WAN Q. Clinical efficacy of entecavir combined with silybin for chronic hepatitis B complicated with fatty liver[J]. Chin J Clin Ration Drug Use, 2019, 12(15): 23-25. DOI: 10.15887/j.cnki.13-1389/r.2019.15.011. 赵波, 戚永花, 万强. 恩替卡韦联合水飞蓟宾治疗慢性乙型肝炎并脂肪肝的临床疗效[J]. 临床合理用药杂志, 2019, 12(15): 23-25. DOI: 10.15887/j.cnki.13-1389/r.2019.15.011.
[40]	FAN JG, CHEN GF, JI D, et al. Long-term disease progression in chronic hepatitis B Chinese patients with comorbid nonalcoholic fatty liver disease[J]. J Hepatol, 2017, 66(1): s416-s417. DOI: 10.1016/S0168-8278(17)31194-7.
[41]	CHAN AW, WONG GL, CHAN HY, et al. Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B[J]. J Gastroenterol Hepatol, 2017, 32(3): 667-676. DOI: 10.1111/jgh.13536.
[42]	SONG C, ZHU J, GE Z, et al. Spontaneous seroclearance of hepatitis B surface antigen and risk of hepatocellular carcinoma[J]. Clin Gastroenterol Hepatol, 2019, 17(6): 1204-1206. DOI: 10.1016/j.cgh.2018.08.019.
[43]	ANGULO P, KLEINER DE, DAM-LARSEN S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease[J]. Gastroenterology, 2015, 149(2): 389-397. e10. DOI: 10.1053/j.gastro.2015.04.043.
[44]	CHOI H, BROUWER WP, ZANJIR W, et al. Nonalcoholic steatohepatitis is associated with liver-related outcomes and all-cause mortality in chronic hepatitis B[J]. Hepatology, 2020, 71(2): 539-548. DOI: 10.1002/hep.30857.
[45]	YOUNOSSI ZM, LOOMBA R, RINELLA ME, et al. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J]. Hepatology, 2018, 68(1): 361-371. DOI: 10.1002/hep.29724.
[46]	LI J, CHEUNG RC, NGUYEN MH. Letter to the editor: Chronic hepatitis B and nonalcoholic steatohepatitis: Is "fat" all bad?[J]. Hepatology, 2020, 71(2): 768. DOI: 10.1002/hep.30983.